​
​

Merck (MRK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRK Stock Forecast

Merck stock forecast is as follows: an average price target of $128.89 (represents a 29.07% upside from MRK’s last price of $99.86) and a rating consensus of 'Buy', based on 24 wall street analysts offering a 1-year stock forecast.

MRK Price Target

The average price target for Merck (MRK) is $128.89 based on 1-year price targets from 24 Wall Street analysts in the past 3 months, with a price target range of $294.00 to $80.00. This represents a potential 29.07% upside from MRK's last price of $99.86.

MRK Analyst Ratings

Buy

According to 24 Wall Street analysts, Merck's rating consensus is 'Buy'. The analyst rating breakdown for MRK stock is 0 'Strong Buy' (0.00%), 22 'Buy' (91.67%), 2 'Hold' (8.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Merck Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 15, 2024Akash TewariJefferies--50.47%48.21%
Nov 01, 2024Evan David SeigermanBMO Capital--33.49%36.19%
Oct 09, 2024Trung HuynhUBS--24.91%36.19%
Oct 07, 2024Carter GouldBarclays--27.54%40.20%
Aug 15, 2024Akash TewariJefferies--29.53%47.21%
Jul 31, 2024Colin BristowUBS--25.79%42.20%
Jul 31, 2024Geoff MeachamBank of America Securities--25.86%45.20%
Jun 12, 2024Mohit BansalWells Fargo--6.83%40.20%
May 30, 2024Evan David SeigermanBMO Capital--15.89%48.21%
Mar 27, 2024Truist Financial--8.55%42.20%
Row per page
Go to

The latest Merck stock forecast, released on Nov 15, 2024 by Akash Tewari from Jefferies, set a price target of $148.00, which represents a 50.47% increase from the stock price at the time of the forecast ($98.36), and a 48.21% increase from MRK last price ($99.86).

Merck Price Target by Period

1M3M12M
# Anlaysts2413
Avg Price Target$142.00$140.00$141.23
Last Closing Price$99.86$99.86$99.86
Upside/Downside42.20%40.20%41.43%

In the current month, the average price target of Merck stock is $142.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 42.20% increase as opposed to Merck's last price of $99.86. This month's average price target is up 1.43% compared to last quarter, and up 0.55% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 01, 2024Leerink PartnersOutperformOutperformHold
Oct 17, 2024BernsteinMarket PerformInitialise
Oct 09, 2024UBSBuyBuyHold
Oct 07, 2024BarclaysOverweightOverweightHold
Sep 16, 2024Wells FargoBuyBuyHold
Sep 16, 2024UBSUnderperformUnderperformHold
Sep 13, 2024NeedhamHoldHoldHold
Sep 03, 2024Cowen & Co.BuyBuyHold
Aug 15, 2024JefferiesBuyBuyHold
Aug 05, 2024Goldman SachsBuyBuyHold
Row per page
Go to

Merck's last stock rating was published by Leerink Partners on Nov 01, 2024. The company gave MRK a "Outperform" rating, the same as its previous rate.

Merck Financial Forecast

Merck Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue---------$15.96B$15.04B$14.49B$13.83B$14.96B$14.59B$15.90B$13.52B$13.15B$11.40B$12.08B$12.52B$12.55B$10.87B$12.06B$11.87B$12.40B$11.76B$10.82B$10.04B$9.43B
Avg Forecast$16.73B$16.75B$16.80B$16.28B$15.53B$16.47B$15.87B$15.21B$14.49B$15.30B$14.44B$13.79B$13.66B$14.07B$13.86B$14.56B$13.16B$12.32B$11.23B$12.61B$12.67B$12.21B$10.40B$11.48B$11.98B$11.64B$10.96B$10.47B$9.56B$8.90B
High Forecast$17.15B$17.18B$17.23B$16.70B$15.79B$16.50B$15.87B$15.21B$14.88B$15.57B$14.81B$14.14B$14.01B$14.07B$13.86B$14.56B$13.16B$12.32B$11.23B$12.61B$12.67B$12.21B$10.40B$11.48B$11.98B$11.64B$10.96B$10.47B$11.47B$10.68B
Low Forecast$16.35B$16.37B$16.42B$15.91B$15.15B$16.44B$15.87B$15.21B$14.26B$14.60B$14.12B$13.48B$13.35B$14.07B$13.86B$14.56B$13.16B$12.32B$11.23B$12.61B$12.67B$12.21B$10.40B$11.48B$11.98B$11.64B$10.96B$10.47B$7.65B$7.12B
# Analysts11121153471599131313137777916811711771710
Surprise %---------1.04%1.04%1.05%1.01%1.06%1.05%1.09%1.03%1.07%1.02%0.96%0.99%1.03%1.05%1.05%0.99%1.07%1.07%1.03%1.05%1.06%

Merck's average Quarter revenue forecast for Dec 23 based on 7 analysts is $14.49B, with a low forecast of $14.26B, and a high forecast of $14.88B. MRK's average Quarter revenue forecast represents a -9.23% decrease compared to the company's last Quarter revenue of $15.96B (Sep 23).

Merck EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11121153471599131313137777916811711771710
EBITDA---------$6.00B$-4.86B$3.87B$3.54B$4.20B$5.21B$5.67B$4.89B$6.22B$2.94B$4.58B$-885.00M$4.48B$4.77B$4.87B$3.94B$3.42B$4.49B$4.23B$2.66B$3.37B
Avg Forecast$4.78B$4.79B$4.80B$4.65B$4.44B$4.71B$4.54B$6.26B$4.14B$4.37B$4.13B$5.69B$4.43B$3.86B$3.80B$5.17B$3.61B$3.38B$3.08B$5.23B$3.47B$3.35B$2.85B$4.29B$3.28B$3.19B$3.00B$3.59B$2.53B$3.17B
High Forecast$4.90B$4.91B$4.92B$4.77B$4.51B$4.72B$4.54B$7.51B$4.25B$4.45B$4.23B$6.83B$5.31B$3.86B$3.80B$6.21B$3.61B$3.38B$3.08B$6.28B$3.47B$3.35B$2.85B$5.15B$3.28B$3.19B$3.00B$4.31B$3.03B$3.80B
Low Forecast$4.67B$4.68B$4.69B$4.55B$4.33B$4.70B$4.54B$5.01B$4.08B$4.17B$4.03B$4.55B$3.54B$3.86B$3.80B$4.14B$3.61B$3.38B$3.08B$4.19B$3.47B$3.35B$2.85B$3.43B$3.28B$3.19B$3.00B$2.87B$2.02B$2.54B
Surprise %---------1.37%-1.18%0.68%0.80%1.09%1.37%1.10%1.35%1.84%0.95%0.88%-0.25%1.34%1.67%1.14%1.20%1.07%1.49%1.18%1.05%1.06%

7 analysts predict MRK's average Quarter EBITDA for Dec 23 to be $4.14B, with a high of $4.25B and a low of $4.08B. This is -30.96% lower than Merck's previous annual EBITDA (Sep 23) of $6.00B.

Merck Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11121153471599131313137777916811711771710
Net Income---------$4.75B$-5.97B$2.82B$3.02B$3.25B$3.94B$4.31B$3.82B$4.57B$1.54B$3.18B$-2.09B$2.94B$3.00B$3.22B$2.36B$1.90B$2.67B$2.92B$736.00M$1.55B
Avg Forecast$5.54B$6.52B$6.16B$5.78B$4.68B$3.77B$5.51B$4.33B$-275.62M$4.96B$-5.54B$3.94B$3.40B$4.34B$4.33B$3.58B$3.88B$3.93B$3.33B$3.63B$3.36B$3.49B$2.57B$2.83B$2.79B$3.01B$2.81B$2.48B$699.20M$1.46B
High Forecast$5.73B$6.73B$6.37B$5.97B$5.25B$3.84B$5.51B$5.20B$-61.25M$5.29B$-5.38B$4.73B$4.09B$4.34B$4.33B$4.30B$3.88B$3.93B$3.33B$4.35B$3.36B$3.49B$2.57B$3.40B$2.79B$3.01B$2.81B$2.97B$839.04M$1.75B
Low Forecast$5.38B$6.33B$5.98B$5.61B$4.44B$3.70B$5.50B$3.47B$-428.74M$4.56B$-5.72B$3.15B$2.72B$4.34B$4.33B$2.86B$3.88B$3.93B$3.33B$2.90B$3.36B$3.49B$2.57B$2.27B$2.79B$3.01B$2.81B$1.98B$559.36M$1.17B
Surprise %---------0.96%1.08%0.72%0.89%0.75%0.91%1.20%0.98%1.16%0.46%0.88%-0.62%0.84%1.17%1.14%0.85%0.63%0.95%1.18%1.05%1.06%

Merck's average Quarter net income forecast for Dec 23 is $-275.62M, with a range of $-428.74M to $-61.25M. MRK's average Quarter net income forecast represents a -105.81% decrease compared to the company's last Quarter net income of $4.75B (Sep 23).

Merck SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11121153471599131313137777916811711771710
SG&A---------$2.52B$2.70B$2.48B$2.69B$2.52B$2.51B$2.32B$2.83B$2.34B$2.28B$2.63B$3.08B$2.45B$2.38B$2.56B$2.89B$2.59B$2.71B$2.42B$2.51B$2.41B
Avg Forecast$3.29B$3.30B$3.31B$3.20B$3.06B$3.24B$3.12B$2.33B$2.85B$3.01B$2.84B$2.12B$2.56B$2.77B$2.73B$1.93B$2.59B$2.42B$2.21B$3.00B$2.49B$2.40B$2.05B$2.25B$2.36B$2.29B$2.16B$2.06B$2.38B$2.27B
High Forecast$3.38B$3.38B$3.39B$3.29B$3.11B$3.25B$3.12B$2.80B$2.93B$3.06B$2.92B$2.55B$3.08B$2.77B$2.73B$2.32B$2.59B$2.42B$2.21B$3.61B$2.49B$2.40B$2.05B$2.70B$2.36B$2.29B$2.16B$2.47B$2.86B$2.72B
Low Forecast$3.22B$3.22B$3.23B$3.13B$2.98B$3.24B$3.12B$1.87B$2.81B$2.87B$2.78B$1.70B$2.05B$2.77B$2.73B$1.54B$2.59B$2.42B$2.21B$2.40B$2.49B$2.40B$2.05B$1.80B$2.36B$2.29B$2.16B$1.65B$1.91B$1.81B
Surprise %---------0.84%0.95%1.17%1.05%0.91%0.92%1.20%1.09%0.96%1.03%0.88%1.24%1.02%1.16%1.14%1.23%1.13%1.26%1.18%1.05%1.06%

Merck's average Quarter SG&A projection for Dec 23 is $2.85B, based on 7 Wall Street analysts, with a range of $2.81B to $2.93B. The forecast indicates a 13.22% rise compared to MRK last annual SG&A of $2.52B (Sep 23).

Merck EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11121153471599131313137777916811711771710
EPS---------$1.87$-2.35$1.11$1.19$1.28$1.56$1.70$1.51$1.81$0.61$1.26$-0.83$1.16$1.19$1.28$0.93$0.75$1.04$1.13$0.27$0.57
Avg Forecast$2.18$2.56$2.43$2.28$1.84$1.48$2.17$1.89$-0.11$1.95$-2.18$1.32$1.53$1.71$1.70$1.83$1.53$1.55$1.31$1.53$1.32$1.37$1.01$1.28$1.10$1.18$1.10$1.00$0.95$0.78
High Forecast$2.25$2.65$2.51$2.35$2.07$1.51$2.17$1.89$-0.02$2.08$-2.12$1.38$1.59$1.71$1.70$1.83$1.53$1.55$1.31$1.53$1.32$1.37$1.01$1.28$1.10$1.18$1.10$1.00$1.14$0.94
Low Forecast$2.12$2.49$2.35$2.21$1.75$1.46$2.17$1.88$-0.17$1.79$-2.25$1.27$1.49$1.71$1.70$1.83$1.53$1.55$1.31$1.53$1.32$1.37$1.01$1.28$1.10$1.18$1.10$1.00$0.76$0.62
Surprise %---------0.96%1.08%0.84%0.78%0.75%0.92%0.93%0.99%1.17%0.47%0.82%-0.63%0.85%1.18%1.00%0.85%0.63%0.94%1.13%0.28%0.73%

According to 7 Wall Street analysts, Merck's projected average Quarter EPS for Dec 23 is $-0.11, with a low estimate of $-0.17 and a high estimate of $-0.02. This represents a -105.80% decrease compared to MRK previous annual EPS of $1.87 (Sep 23).

Merck Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer--78.11%Hold
MRKMerck--29.07%Buy
JNJJohnson & Johnson--15.20%Buy
BMYBristol-Myers Squibb Company--12.48%Hold
AMGNAmgen--4.11%Buy
LLYEli Lilly and Company--3.76%Buy
ABBVAbbVie--0.91%Buy
GILDGilead Sciences---8.90%Buy

MRK Forecast FAQ

Is Merck a good buy?

Yes, according to 24 Wall Street analysts, Merck (MRK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 22 'Buy' recommendations, accounting for 91.67% of MRK's total ratings.

What is MRK's price target?

Merck (MRK) average price target is $128.89 with a range of $80 to $294, implying a 29.07% from its last price of $99.86. The data is based on 24 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Merck stock go up soon?

According to Wall Street analysts' prediction for MRK stock, the company can go up by 29.07% (from the last price of $99.86 to the average price target of $128.89), up by 194.41% based on the highest stock price target, and down by -19.89% based on the lowest stock price target.

Can Merck stock reach $150?

MRK's highest twelve months analyst stock price target of $294 supports the claim that Merck can reach $150 in the near future.

What is Merck's current price target trend?

2 Wall Street analysts forecast a $142 price target for Merck (MRK) this month, up 42.20% from its last price of $99.86. Compared to the last 3 and 12 months, the average price target increased by 40.20% and increased by 41.43%, respectively.

What are Merck's analysts' financial forecasts?

Merck's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $63.08B (high $63.37B, low $62.67B), average EBITDA is $19.94B (high $21.27B, low $18.57B), average net income is $18.29B (high $19.81B, low $17.1B), average SG&A $11.76B (high $12.28B, low $11.21B), and average EPS is $7.38 (high $7.64, low $7.25). MRK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $66.56B (high $68.25B, low $65.05B), average EBITDA is $19.02B (high $19.51B, low $18.59B), average net income is $24B (high $24.8B, low $23.3B), average SG&A $13.1B (high $13.44B, low $12.81B), and average EPS is $9.45 (high $9.76, low $9.17).

Did the MRK's actual financial results beat the analysts' financial forecasts?

Based on Merck's last annual report (Dec 2022), the company's revenue was $59.28B, beating the average analysts forecast of $56.13B by 5.61%. Apple's EBITDA was $18.62B, beating the average prediction of $17.26B by 7.90%. The company's net income was $14.52B, missing the average estimation of $15.66B by -7.27%. Apple's SG&A was $10.04B, beating the average forecast of $9.99B by 0.53%. Lastly, the company's EPS was $5.73, missing the average prediction of $6.77 by -15.36%. In terms of the last quarterly report (Sep 2023), Merck's revenue was $15.96B, beating the average analysts' forecast of $15.3B by 4.35%. The company's EBITDA was $6B, beating the average prediction of $4.37B by 37.21%. Merck's net income was $4.74B, missing the average estimation of $4.96B by -4.40%. The company's SG&A was $2.52B, missing the average forecast of $3.01B by -16.34%. Lastly, the company's EPS was $1.87, missing the average prediction of $1.95 by -4.27%